Transaction DateRecipientSharesTypePriceValue
3rd February 2021Gisela Schwab9,745Grant/award etc.$0.00
3rd February 2021Michael Morrissey23,238Grant/award etc.$0.00
3rd February 2021Michael Morrissey65,190Payment by withholding$22.56$1,470,686.40
3rd February 2021Christopher J. Senner59,411Grant/award etc.$0.00
3rd February 2021Christopher J. Senner9,745Grant/award etc.$0.00
3rd February 2021Gisela Schwab14,982Payment by withholding$22.56$337,993.92
3rd February 2021Peter Lamb71,293Grant/award etc.$0.00
3rd February 2021Peter Lamb9,370Grant/award etc.$0.00
3rd February 2021Gisela Schwab71,293Grant/award etc.$0.00
3rd February 2021Christopher J. Senner18,206Payment by withholding$22.56$410,727.36
Exelixis
Exelixis logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.


Exelixis, Inc. engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994.


Ticker: EXEL
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 939767
Employees: 484
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $527 M (0%)
Receivables, Net, Current: $121 M (1%)
Inventory, Net: $17 M (28%)
Assets, Current: $1 B (37%)
Property, Plant and Equipment, Net: $52 M (7%)
Other Assets, Noncurrent: $61 M (13%)
Assets: $2 B (8%)
Accounts Payable, Current: $9 M (-21%)
Liabilities, Current: $143 M (0%)
Other Liabilities, Noncurrent: $7 M (207%)
Liabilities: $213 M (6%)
Common Stock, Value, Issued: $309 Th (1%)
Common Stock, Shares, Issued: $309 M (1%)
Retained Earnings (Accumulated Deficit): $444 M (-20%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $8 M (155%)
Stockholders' Equity (Parent): $2 B (0%)
Liabilities and Equity: $2 B (8%)
Revenue: $259 M (-46%)
Cost of Revenue: $9 M (-50%)
Research and Development: $115 M (-46%)
Operating Income/Loss: $76 M (-41%)
Income before taxes: $81 M (-42%)
Provision for income taxes: $14 M (-45%)
EPS (basic): $0.22 (0%)
EPS (diluted): $0.21 (0%)